Aurenar (Seed)
Funding Details
Awarder
Inbox
Date Award
July 28, 2026
Vertical
Healthcare
Funding Amount
$5,700,000
Company Info
Founders
Eric Leuthardt, MD
Market
ICU patients
Location
St. Louis, MO, USA
Coinvestors
American Heart Association Ventures, BJC Health, Kaleida Capital, Solas Bioventures
Company Description

Aurenar is a company developing a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in ICU patients. The company's transauricular vagus nerve stimulation (taVNS) device targets the body's inflammatory response to improve outcomes, lower total cost of care, and transform critical care management.

Links